.png){kind=icon}
.png){kind=icon}
Return
BCMA-Targeted Therapy Enables Combined Haploidentical Stem Cell and Kidney Transplantation in a Highly Sensitized Patient
.png){kind=icon}
PRE
AI
K
V
A
Y
DOI：10.1016/j.ajt.2026.07.019.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
A 64-year-old woman with multiple myeloma and end-stage kidney disease was initially deemed ineligible for combined haploidentical hematopoietic stem cell and kidney transplantation due to positive flow cytometry crossmatch from high levels of donor-specific anti-HLA antibodies (DSA).
Journal
IF:
8.2
Papers:
1.1W
Citations:
2.6W
Organization
Cited Papers